Magalhães-Costa Pedro, Matos Leopoldo, Chagas Cristina
Department of Gastroenterology, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal.
BMJ Case Rep. 2015 May 2;2015:bcr2014207928. doi: 10.1136/bcr-2014-207928.
The 5-aminosalicylate is widely prescribed in inflammatory bowel disease patients. Its potential for renal damage has been seldom described. We report a case of a 23-year-old man who started 5-aminosalicylate after being diagnosed with ulcerative colitis. One year after, a significant decline on his creatinine clearance was noted, however, at that time, he was on an acute flare of his bowel disease and the 5-aminosalicylate dose was increased. Six months later, his renal function kept worsening and, on drug-induced toxicity suspicion, 5-aminosalicylate was halted and a kidney biopsy demonstrated a chronic tubulointerstitial nephritis. Steroids and azathioprine were started leading to partial recovery and stabilisation of his renal function. Physicians who prescribe 5-aminosalicylate to patients with inflammatory bowel disease should be aware of this adverse event.
5-氨基水杨酸酯在炎症性肠病患者中被广泛使用。其导致肾损伤的可能性鲜有描述。我们报告一例23岁男性病例,该患者在被诊断为溃疡性结肠炎后开始使用5-氨基水杨酸酯。一年后,其肌酐清除率显著下降,然而,当时他正处于肠道疾病的急性发作期,5-氨基水杨酸酯的剂量增加了。六个月后,他的肾功能持续恶化,出于对药物诱导毒性的怀疑,停用了5-氨基水杨酸酯,肾脏活检显示为慢性肾小管间质性肾炎。开始使用类固醇和硫唑嘌呤后,其肾功能部分恢复并稳定。给炎症性肠病患者开5-氨基水杨酸酯的医生应注意到这一不良事件。